LIVE
COURSES
2016
February 15–19
June 04–07
June 17–18
Huntley Lodge
Big Sky, MT
Mexico City, Mexico
The Westin Houston
Memorial City
Houston, TX
38th Annual Cardiology at
Big Sky
World Heart Federation |
World Congress of Cardiology
& Cardiovascular Health 2016
Care of the Athletic Heart:
Translating Clinical Science
into Practice Strategies
B:7.875 in
T:7.5 in
S:7 in
Add Corlanor ® to maximally tolerated doses of beta-blockers and help give
appropriate patients with heart rate ≥ 70 bpm and stable, symptomatic chronic HF...
MORE HOME. LESS HOSPITAL.
February 18–20
2016 Cardiovascular Summit:
Solutions for Thriving in a
Time of Change
The Cosmopolitan of Las Vegas
Las Vegas, NV
April 02–04
ACC.16 65th Annual Scientific
Session & Expo
McCormick Center
Chicago, IL
May 05–07
Recent Advances in Clinical
Nuclear Cardiology and
Cardiac CT: State of the Art
Updates and 101 EvidenceBased Case Reviews
Capital Hilton
Washington, DC
Learn how you can DO MORE with Corlanor® to reduce the risk
of hospitalization for worsening heart failure (HF)
1
CorlanorHCP.com
Indication
Corlanor® (ivabradine) is indicated to reduce the risk of hospitalization
for worsening heart failure in patients with stable, symptomatic
chronic heart failure with left ventricular ejection fraction ≤ 35%, who
are in sinus rhythm with resting heart rate ≥ 70 beats per minute and
either are on maximally tolerated doses of beta-blockers or have a
contraindication to beta-blocker use.
Important Safety Information
Contraindications: Corlanor® is contraindicated in patients with
acute decompensated heart failure, blood pressure < 90/50 mmHg,
sick sinus syndrome, sinoatrial block, 3rd degree atrioven